NEO - NeoGenomics, Inc.
15.50 0.00 (0.00%)
After hours: 4:34PM EST
| Previous Close | 15.30 |
| Open | 15.25 |
| Bid | 12.79 x 1800 |
| Ask | 15.69 x 900 |
| Day's Range | 15.15 - 15.70 |
| 52 Week Range | 7.08 - 19.04 |
| Volume | 1,508,729 |
| Avg. Volume | 1,471,112 |
| Market Cap | 1.464B |
| Beta (3Y Monthly) | 0.51 |
| PE Ratio (TTM) | 196.20 |
| EPS (TTM) | 0.08 |
| Earnings Date | Feb 19, 2019 - Feb 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.88 |
- Markit•9 hours ago
See what the IHS Markit Score report has to say about Neogenomics Inc.
# Neogenomics Inc ### NASDAQ:NEO View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Negative Short interest is moderately high for NEO with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 15. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $371 million over the last one-month into ETFs that hold NEO are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•8 days ago
Here's Why NeoGenomics Rocketed Higher Today
It was nothing the medical diagnostics company did.
- PR Newswire•9 days ago
NeoGenomics Set to Join S&P SmallCap 600
NEW YORK , Jan. 8, 2019 /PRNewswire/ -- NeoGenomics Inc. (NASD: NEO) will replace Engility Holdings Inc. (NYSE: EGL) in the S&P SmallCap 600 effective prior to the open of trading on Monday, January 14, ...
- Zacks•23 days ago
Is NeoGenomics (NEO) Stock Outpacing Its Medical Peers This Year?
Is (NEO) Outperforming Other Medical Stocks This Year?
- Zacks•27 days ago
NeoGenomics (NEO) Stock Moves -1.04%: What You Should Know
NeoGenomics (NEO) closed the most recent trading day at $11.46, moving -1.04% from the previous trading session.
Markit•28 days agoSee what the IHS Markit Score report has to say about Neogenomics Inc.
Short interest is low for NEO with fewer than 5% of shares on loan. Over the last month, ETFs holding NEO are favorable, with net inflows of $2.07 billion. Index (PMI) data, output in the Healthcare sector is rising.
- Insider Monkey•last month
NeoGenomics, Inc. (NEO): Hedge Funds Are Snapping Up
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]
- Barrons.com•last month
GE Sells Last of Its NeoGenomics Stock for $130 Million
A GE unit sold 10.8 million shares of the genetics-testing firm to underwriters, who sold the stock via a secondary offering.
Zacks•last monthThe Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
- Zacks•last month
5 Healthcare Bets to Stay in Investors Good Books Next Year
Based on a few key factors, we zero in on five stocks that show promise to retain the bull run in 2019.
- GlobeNewswire•last month
NeoGenomics Appoints Dr. Lawrence M. Weiss as Chief Scientific Officer
NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced the appointment of Lawrence M. Weiss, M.D. as Chief Scientific Officer. Dr. Weiss joined NeoGenomics and has served as Medical Director and Laboratory Director for NeoGenomics Laboratories since joining NeoGenomics as part of the Clarient acquisition in 2015. “We are delighted to announce Dr. Weiss as our Chief Scientific Officer,” said Douglas M. VanOort, NeoGenomics’ Chairman and CEO. “Larry is a highly-regarded thought-leader in the oncology and pathology community, with years of medical and scientific leadership experience at NeoGenomics and other organizations.
- GlobeNewswire•last month
NeoGenomics Announces Secondary Offering of Common Stock by Selling Stockholder
NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced that GE Medical Systems Information Technologies, Inc. (“GE Info Tech”) intends to offer for sale in an underwritten secondary offering 10,835,145 shares of common stock of the Company pursuant to a shelf registration statement the Company has filed with the Securities and Exchange Commission (the “SEC”). NeoGenomics, Inc. will not offer any newly issued shares or receive any proceeds from the sale of shares by GE Info Tech in the offering. Morgan Stanley is acting as the sole bookrunner for the offering.
- GlobeNewswire•last month
NeoGenomics Completes Acquisition of Genoptix, Inc.
NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, announced today that it has completed the acquisition of the parent company of Genoptix, Inc. for $125 million in cash, as adjusted by working capital and other adjustments, and 1 million shares of NeoGenomics common stock. Genoptix is a leading clinical oncology laboratory, specializing in hematology and solid tumor testing. The acquisition expands NeoGenomics’ reach into oncology practices, and significantly accelerates the company’s progress towards key scale and growth objectives.
- Zacks•last month
Is NeoGenomics (NEO) Outperforming Other Medical Stocks This Year?
Is (NEO) Outperforming Other Medical Stocks This Year?
- Zacks•last month
QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach
The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.
- GlobeNewswire•2 months ago
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018 HILDEN, Germany and GERMANTOWN, Md. and FORT MYERS, Fla., Nov. 30, 2018 -- QIAGEN N.V. (NYSE:.
- Business Wire•2 months ago
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs
Partners discuss efforts to accelerate precision medicine solutions at ASH 2018
- Zacks•2 months ago
Eyenovia Initiates Phase III Study for Mydriasis Candidate
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
- Simply Wall St.•2 months ago
What Kind Of Investor Owns Most Of NeoGenomics Inc (NASDAQ:NEO)?
The big shareholder groups in NeoGenomics Inc (NASDAQ:NEO) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a Read More...
- GlobeNewswire•2 months ago
Research Report Identifies Ironwood Pharmaceuticals, The AES, Accuray, Ball, Park Hotels & Resorts, and NeoGenomics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NEO earnings conference call or presentation 30-Oct-18 12:30pm GMT
Q3 2018 Neogenomics Inc Earnings Call
- Investor's Business Daily•3 months ago
Dow Jones Leads Fragile Rebound; Will This Sector Head A Recovery?
The Dow Jones industrial average is leading major indexes in a mild rebound. But it's unclear which sector could lead the market back up.
- Zacks•3 months ago
NeoGenomics (NEO) Q3 Earnings and Revenues Top Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 66.67% and 4.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
